Abstract:1134 Objectives: Liposome, as a FDA proved nano-sized drug carrier material with excellent biodegradability and biocompatibility, has been extensively used in tumor chemotherapy. Liposomes not only can encapsulate small drug molecules or signaling molecules, but also can be easily and conveniently modified externally, which is an unique advantage for developing multifunctional and theranostic nanoparticle probes. Liposomes have been radiolabeled and applied mostly for tumor detection, but very rarely for radiotherapy. Herein, 177Lu-labeled DiR-encapsulated liposome was evaluated for SPECT/Optical dual-modality imaging and biodistribution in Lewis lung cancer (LLC) xenografts. Furthermore, the therapeutic efficacy of 177Lu-labeled Dox-encapsulated liposome for combination radio-chemotherapy was firstly assessed in LLC xenografts. Methods: Biodistribution, SPECT/Optical dual-modality imaging and maximum tolerated dose (MTD) studies of 177Lu-Liposome were performed. The radiotherapy studies were begun when the tumor reached 50~80 mm3 and were compared with liposome encapsulated Doxorubicin or in combination. The liposome encapsulated Doxorubicin was given once every three days for three times totally. Tumor size and body weight were monitored every other day. When the tumor volume reached 1500 mm3 or more than 20% of the weight loss, the experiment was concluded. Results: 177Lu-Liposome are slowly cleared from the blood and at 24 h post-injection, tumor uptake reached the highest (7.55 ± 3.85%ID/g); until 72 h post-injection, the tumor is still maintaining a high uptake (5.02 ± 2.75%ID/g). The tumors were clearly visualized by the SPECT/Optical imaging. Compared with liposome encapsulated Doxorubicin alone, the 177Lu-liposome or the combination of 177Lu-liposome with doxorubicin has further notably inhibited tumor growth. From the fifth day post-treatment, the combination therapy of 177Lu-Dox-liposome has an enhanced inhibition of tumor growth than that of Dox-liposome or 177Lu-liposome, and this advantage has been maintained until the experiment was concluded. Conclusions: The 177Lu-radiolabeled payloaded liposome was prepared as a multifunctional nanoprobe. Passive targeted therapy of 177Lu-liposome is effective in LLC tumor model. 177Lu-liposome radiotherapy alone or combination with Dox-liposome, can remarkably suppress the tumor growth in LLC tumor model. Development of the multimodality imaging nanoprobe and its potential for the diagnosis and treatment is in progress.

Ligand Conjugated Low-Density Lipoprotein Nanoparticles For Enhanced Optical Cancer Imaging In Vivo

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Excretable Lanthanide Nanoparticle For Biomedical Imaging And Surgical Navigation In The Second Near-Infrared Window

HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting.

Low-density lipoprotein decorated and indocyanine green loaded silica nanoparticles for tumor-targeted photothermal therapy of breast cancer

Outer-Frame-Degradable Nanovehicles Featuring Near-Infrared Dual Luminescence for in Vivo Tracking of Protein Delivery in Cancer Therapy

Tumor-Activatable Nanoparticles Target Low-Density Lipoprotein Receptor to Enhance Drug Delivery and Antitumor Efficacy

Erythrocyte Membrane-Coated Upconversion Nanoparticles with Minimal Protein Adsorption for Enhanced Tumor Imaging

Near-Infrared-Light-Responsive Lipid Nanoparticles As an Intelligent Drug Release System for Cancer Therapy

Ligand-Specific Nano-Contrast Agents Promote Enhanced Breast Cancer CT Detection at 0.5 mg Au

In Vivo Bioorthogonal Labeling of Rare-Earth Doped Nanoparticles for Improved NIR-II Tumor Imaging by Extracellular Vesicle-Mediated Targeting

Redox-Activated Light-Up Nanomicelle for Precise Imaging-Guided Cancer Therapy and Real-Time Pharmacokinetic Monitoring

Ultrasmall Conjugated Polymer Nanoparticles with High Specificity for Targeted Cancer Cell Imaging

Near-Infrared-II Nanoparticles for Cancer Imaging of Immune Checkpoint Programmed Death-Ligand 1 and Photodynamic/Immune Therapy

Emissive Lipid Nanoparticles as Biophotonic Contrast Agent for Site-Selective Solid Tumor Imaging in Pre-Clinical Models

A Self-Assembled "Albumin-Conjugate" Nanoprobe for Near Infrared Optical Imaging of Subcutaneous and Metastatic Tumors.

Lipid-Based Nanocarrier by Targeting with LHRH Peptide: A Promising Approach for Prostate Cancer Radio-Imaging and Therapy

NIR-Light-Triggered Anticancer Strategy for Dual-Modality Imaging-Guided Combination Therapy via a Bioinspired Hybrid PLGA Nanoplatform

Lu-177-labeled Payloaded Liposome for SPECT/Optical Dual-modality Imaging and Combined Radio- and Chemotherapy in LLC Mice Model

A PEGylation-Free Biomimetic Porphyrin Nanoplatform for Personalized Cancer Theranostics

A stable NIR fluorescent probe for imaging lipid droplets in triple-negative breast cancer